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ABSTRACT: Complete resection of tumor lesions in advanced
stage ovarian cancer patients is of utmost importance, since the
extent of residual disease after surgery strongly aﬀects survival.
Intraoperative imaging may be useful to improve surgery in these
patients. Farletuzumab is a humanized IgG1 antibody that
speciﬁcally recognizes the folate receptor alpha (FRα). Labeled
with a radiolabel and a ﬂuorescent dye, farletuzumab may be
used for the intraoperative detection of ovarian cancer lesions.
The current aim is to demonstrate the feasibility of FRα-targeted
dual-modality imaging using 111In-farletuzumab-IRDye800CW
in an intraperitoneal ovarian cancer model. Biodistribution studies were performed 3 days after injection of 3, 10, 30, or 100 μg of
111In-farletuzumab-IRDye800CW in mice with subcutaneous IGROV-1 tumors (5 mice per group). In mice with intraperitoneal
IGROV-1 tumors the nonspeciﬁc uptake of 111In-farletuzumab-IRDye800CW was determined by coinjecting an excess of
unlabeled farletuzumab. MicroSPECT/CT and ﬂuorescence imaging were performed 3 days after injection of 10 μg of 111In-
farletuzumab-IRDye800CW. FRα expression in tumors was determined immunohistochemically. Optimal tumor-to-blood-ratios
(3.4−3.7) were obtained at protein doses up to 30 μg. Multiple intra-abdominal tumor lesions were clearly visualized by
microSPECT/CT, while uptake in normal tissues was limited. Fluorescence imaging was used to visualize and guide resection of
superﬁcial tumors. Coinjection of an excess of unlabeled farletuzumab signiﬁcantly decreased tumor uptake of 111In-farletuzumab-
IRDye800CW (69.4 ± 27.6 versus 18.3 ± 2.2% ID/g, p < 0.05). Immunohistochemical analyses demonstrated that the
radioactive and ﬂuorescent signal corresponded with FRα-expressing tumor lesions. FRα-targeted SPECT/ﬂuorescence imaging
using 111In-farletuzumab-IRDye800CW can be used to detect ovarian cancer in vivo and could be a valuable tool for enhanced
intraoperative tumor visualization in patients with intraperitoneal metastases of ovarian cancer.
KEYWORDS: ovarian cancer, molecular imaging, near-infrared ﬂuorescence imaging, image-guided surgery,
folate receptor alpha targeted imaging
■ INTRODUCTION
Epithelial ovarian cancer is also called the “silent lady killer”,
since clinical symptoms arise relatively late.1 As a consequence,
approximately 70% of patients present with disease extending
to other structures within or outside the pelvis at time of
diagnosis.1 Ovarian cancer metastasizes primarily throughout
the abdominal cavity, and complete resection of tumor lesions
is of utmost importance.2 These patients can be treated by
primary debulking surgery or by neoadjuvant chemotherapy
followed by surgery (interval debulking).2 In both regimes, the
extent of residual disease after surgery is one of the main
prognostic factors for (progression free) survival.1−4 Especially
in patients previously treated with chemotherapy the distinction
between tumor tissue and benign tissue can be challenging
during surgery, since tumor lesions may shrink or visually
disappear due to chemotherapy.2 Intraoperative tumor-speciﬁc
imaging may be useful to improve surgery of ovarian cancer
patients as it may facilitate accurate and sensitive detection of
tumor tissue.
Van Dam et al. have shown that FRα-targeted ﬂuorescence
imaging using folate-FITC (EC17) can be beneﬁcial in staging
and debulking of metastatic ovarian cancer patients.5 The FRα
is overexpressed in approximately 90% of the ovarian
carcinomas, while expression in normal tissue is limited.6,7
Furthermore, the expression of the FRα is not changed by
chemotherapy.8 Therefore, the receptor has been proposed as
an ideal marker for targeted therapies and targeted imaging in
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ovarian cancer patients.9,10 Farletuzumab (also designated as
MORAb-003) is an intact humanized IgG1 antibody that
speciﬁcally recognizes FRα and is investigated as a diagnostic as
well as a therapeutic agent for ovarian cancer.11−13 Phase I/II
therapeutic clinical trials have shown no dose-limiting toxicities,
and a pilot clinical study has shown that single photon emission
computed tomography (SPECT) after injection of 111In-
farletuzumab can detect ovarian cancer and metastases.11,12,14,15
Fluorescently labeled farletuzumab may enable intraoperative
imaging, but the limited penetration depth of light in biological
tissues implies that only superﬁcial tumor lesions can be
detected. Therefore, the use of dual-labeled tracers might be
advantageous: the radioactive signal can be used to detect
deeply located tumors, while the ﬂuorescent label allows for
accurate real-time tumor delineation. Several preclinical studies
have shown the feasibility of targeted dual-modality imaging
using monoclonal antibodies.16−22
The aim of the current study is to show the feasibility of
FRα-targeted dual-modality imaging in ovarian cancer using
111In-farletuzumab-IRDye800CW in an intraperitoneal tumor
model.
■ MATERIALS AND METHODS
Animals. Animal studies were performed after approval of
the national committee on animal experiments (CCD) and the
local animal welfare body (AWB). BALB/c nu/nu mice (6−8
weeks old) were obtained from Janvier (Le Genest-Saint-Isle,
France) and acclimatized to laboratory conditions during 1
week. Mice were fed water and animal chow ad libitum. At least
48 h before the start of the image-guided surgery and
biodistribution experiments, mice were fed a folate-free diet.
Daily health monitoring was performed. Mice with ip tumors
were weighed three times a week as part of their welfare
assessment.
Dual-Labeled Antibody Production. Dual-labeled farle-
tuzumab was produced essentially as previously described.17 In
short, 2.5 mg of humanized farletuzumab (5 mg/mL, IgG1,
Morphotek, Exton, PA) was incubated at room temperature
during 1 h with 58 μg of IRDye800CW-NHS ester (LI-COR
biosciences, Lincoln, NE) in 0.1 M NaHCO3, pH 8.5. Next,
farletuzumab-IRDye800CW was incubated with 109 μg of ITC-
DTPA (Macrocyclics, Dallas, TX) in 0.1 M NaHCO3, pH 9.5.
Unconjugated IRDye800CW and ITC-DTPA were removed by
extensive dialysis against 0.25 M ammonium acetate, pH 5.5.
On average 1.7 molecules of IRDye800CW were conjugated
per antibody (substitution ratio) as was determined with the
Ultrospec 2000 UV/visible spectrophotometer (Pharmacia
Biotech, Sweden). The absorption and emission spectra of
DTPA-farletuzumab-IRDye800CW and IRDye800CW were
measured with a microplate reader (Inﬁnite Pro 200, Tecan
Austria GmbH, Groedig, Austria) (Figure S1). The immunor-
eactive fraction of dual-labeled farletuzumab was determined
after 1 h incubation with IGROV-1 cells as described by
Lindmo et al.23 and exceeded 70%. DTPA-farletuzumab-
IRDye800CW was stored in the dark at 4 °C until
radiolabeling.
111InCl3 was purchased from Mallinckrodt Pharmaceuticals
(’s Hertogenbosch, The Netherlands). On the day of the
experiments radiolabeling of DTPA-farletuzumab-IR-
Dye800CW with indium-111 was performed by 30 min
incubation at room temperature in 0.5 M MES buﬀer, pH
5.0. Radiochemical purity was determined by instant thin layer
chromatography (ITLC) on silica gel strips, using 0.1 M
sodium citrate buﬀer, pH 6.0 as mobile phase and always
exceeded 95%. To reach a speciﬁc activity of 1.25 MBq/μg for
SPECT imaging, dual-labeled farletuzumab was puriﬁed after
radiolabeling using a PD10 column with 0.5% BSA/PBS. After
puriﬁcation (ITLC > 95%), 79% of the original amount of
protein was left, and this was supplemented with unlabeled
DTPA-farletuzumab-IRDye800CW to the desired protein dose.
For the dose escalation studies an equivalent of 3 μg of DTPA-
farletuzumab-IRDye800CW per mouse was labeled with
indium-111 and subsequently supplemented to the desired
protein dose with unlabeled DTPA-farletuzumab-IR-
Dye800CW. Before iv injection, the injection volume was
adjusted to 200 μL per mouse with 0.5% BSA/PBS.
Dose Escalation Study (Sc Tumor Model). To determine
the optimal protein dose to perform dual-modality imaging, a
protein dose escalation study was performed in mice with sc
IGROV-1 xenografts. Cells were cultured in RPMI medium
enriched with 10% fetal calf serum and 1% glutamine. Mice
were injected sc with 200 μL of tumor cell suspension (107
cells) on the right ﬂank. When tumors had grown to
approximately 100 to 300 mm3, mice were injected iv with
10 μg of 111In-farletuzumab-IRDye800CW (0.5 MBq). After
approximately 1.5 weeks of tumor growth, mice were injected iv
with 3, 10, 30, or 100 μg of 111In-farletuzumab-IRDye800CW
(5 per group, 0.5 MBq/mouse, 200 μL/mouse). Three days
after injection, ﬂuorescence imaging was performed with the
IVIS Lumina closed-cabinet ﬂuorescence scanner (excitation
745 nm, background correction excitation 640 nm, emission
ﬁlter ICG, ﬁeld of view C, binning medium, f-stop 2).
Additionally, biodistribution studies were performed (see
below).
Dual-Modality Imaging and Image-Guided Surgery
(Ip Tumor Model). To show the feasibility of ﬂuorescence
imaging and ﬂuorescence-guided surgery in a setting relevant
for ovarian cancer, an ip tumor model with IGROV-1 cells was
optimized. As a pilot study to assess tumor growth 12 mice
were injected ip with 106 or 5 × 106 IGROV-1 cells in 500 μL
of RPMI (6 mice per group). Mice were injected iv with dual-
labeled farletuzumab after 3, 7, or 13 days of tumor growth (2
mice per time point per group). Three days later ﬂuorescence
imaging and biodistribution studies were performed (days 6,
10, and 16 respectively).
Next, the feasibility of dual-modality imaging and ﬂuo-
rescence-guided surgery was studied in 8 mice with ip tumors.
Seven days after tumor inoculation (5 × 106 cells), mice
received 10 μg of dual-labeled farletuzumab (12.5 MBq/mouse,
iv). To determine the nonspeciﬁc tumor uptake of dual-labeled
farletuzumab, 3 out of the 8 mice were coinjected with an
excess of unlabeled farletuzumab (1 mg) to block the FRα in
vivo. After 10 days of tumor growth (3 days p.i.) dual-modality
imaging and ﬂuorescence-guided surgery were performed. Mice
were euthanized by O2/CO2 suﬀocation. Then, SPECT/CT
imaging was performed in the USPECT small animal scanner
(Milabs, Utrecht, The Netherlands) using a 1.0 mm mouse
pinhole collimator (2 × 15 min acquisition time, 28 bed
positions). SPECT/CT images were reconstructed using the
MILabs software (Utrecht, The Netherlands; reconstruction
parameters 0.2 mm voxels, 16 subsets, 4 iterations, Gaussian
ﬁlter 1.5) and subsequently analyzed using the Inveon Research
Workplace (Siemens Healthcare, The Netherlands). Next,
ﬂuorescence images were obtained with the IVIS Lumina
closed-cabinet ﬂuorescence scanner (Caliper LifeSciences,
Hopkinton, MA) after removal of the abdominal skin
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(excitation 745 nm, background correction excitation 640 nm,
emission ﬁlter ICG, ﬁeld of view B, binning small, f-stop 2).
After resection of all visible tumor lesions, mice were imaged
again with the IVIS Lumina to check for residual disease.
Finally, biodistribution studies were performed (see below).
Five micrometer sections were cut from formalin-ﬁxed and
paraﬃn-embedded resected tumor tissue and analyzed auto-
radiographically. Sections were exposed for 2 weeks to a
phosphor imaging plate and developed using the Typhoon FLA
7000 phosphor imager (GE Healthcare Life Sciences,
Eindhoven, The Netherlands). Then, the ﬂuorescent signal in
the tumor sections was imaged with the Odyssey CLx ﬂatbed
ﬂuorescence scanner (800 nm channel, recording time 1−5
min, focus 1.0 mm) (LI-COR biosciences, Lincoln, NE). Lastly,
a standard hematoxylin and eosin staining was performed, as
well as a folate-receptor-alpha-staining using the Folate
Receptor alpha IHC Assay Kit (Morphotek, Exton, PA).
Biodistribution Studies. All studies were performed 3 days
after injection of dual-labeled farletuzumab. For biodistribution
studies samples of blood, muscle, heart, lung, spleen, kidney,
pancreas, liver, stomach, duodenum, and tumor lesions were
retrieved. Tissue samples were weighed and measured in a
gamma counter (2480 WIZARD,2 PerkinElmer, Boston, MA)
together with standards of the injected dose in triplicate. The
accumulation of dual-labeled farletuzumab was expressed as
percentage of the injected dose per gram of tissue (% ID/g),
and values are represented as mean ± standard deviation (SD).
Statistical analyses were performed using IBM SPSS Statistics
22.0. In the dose escalation study a one-way ANOVA test with
post hoc Bonferroni correction was performed to test for
signiﬁcant diﬀerences in tumor accumulation between the
diﬀerent dose levels. Tumor uptake in the mice that received an
excess of unlabeled farletuzumab was tested for signiﬁcance
with an independent sample t test. An alpha of 0.05 was used in
all analyses; p < 0.05 was considered signiﬁcant.
■ RESULTS
Dose Escalation Study (Sc Tumor Model). The protein
dose-escalation study revealed tumor-to-blood-ratios of 3.5, 3.4,
3.7, and 2.8 in the 3, 10, 30, and 100 μg dose levels,
respectively. Tumor uptake was 43.6 ± 4.8, 39.9 ± 4.3, 39.3 ±
5.8, and 32.7 ± 3.2% ID/g after injection of 3, 10, 30, and 100
μg dual-labeled farletuzumab respectively (Figure 1). Tumor
uptake after injection of 100 μg of dual-labeled farletuzumab
was signiﬁcantly lower than tumor uptake after injection of 3 μg
(p < 0.05). No signiﬁcant diﬀerences in tumor uptake between
the 3, 10, and 30 μg dose levels were seen. Further studies were
performed with a protein dose of 10 μg of dual-labeled
farletuzumab.
Dual-Modality Imaging and Fluorescence-Guided
Surgery (Ip Tumor Model). Fluorescence imaging clearly
visualized high uptake of dual-labeled farletuzumab in macro-
scopically visible tumor lesions as early as 6 days after tumor
cell injection in 10 out of 12 mice. Tumors were mainly located
around the spleen, in the hepatic hilum and between the
abdominal organs. Two mice that were injected with 106
IGROV-1 cells did not have visible ip tumors, and in one
mouse no tumors could be visualized with ﬂuorescence imaging
(only biodistribution studies were performed in the second
mouse). No tumor lesions outside the abdominal cavity were
observed during extensive macroscopic inspection, and mice
did not develop ascites.
Uptake of 111In-farletuzumab-IRDye800CW was visualized
by microSPECT/CT in multiple intra-abdominal lesions in all
5 mice that were injected with 10 μg/12.5 MBq 111In-
farletuzumab-IRDye800CW (Figures 2a and 2b). After
resection of the abdominal skin, the gross majority of these
hotspots could be localized to macroscopic tumor deposits and
were detectable with ﬂuorescence imaging (Figures 2c and 2d).
For superﬁcial tumors microSPECT images matched with the
corresponding ﬂuorescence images (Figure 2). Intraoperative
ﬂuorescence imaging was used to guide resection of superﬁcial
tumor lesions (Figure 3). After shifting the organs, also deeply
seated tumor lesions could be visualized with ﬂuorescence
imaging (Figure S1a). However, it is more diﬃcult to trace back
the location of deeply located tumors in the abdomen to their
preoperative location on the microSPECT/CT. In addition,
ﬂuorescence imaging revealed multiple lesions throughout the
abdomen, suggestive of submillimeter tumor deposits that are
barely visible to the naked eye (Figures 2d, 4, and S2).
Microscopic tissue studies demonstrated that the radioactive
and ﬂuorescent signal corresponded with FRα-expressing
tumor lesions (Figures 4 and S3). The FRα-staining showed
a very homogeneous FRα expression in the IGROV-1 tumors,
but autoradiography and ﬂuorescence imaging showed that the
distribution of dual-labeled farletuzumab in tumor tissue was
more heterogeneous (Figure S3). This diﬀerence may be due to
diﬀerences in tumor vascularization. Coinjection of an excess of
unlabeled farletuzumab resulted in a signiﬁcant decrease of
dual-labeled farletuzumab in tumor tissue (69.4 ± 27.6 versus
18.3 ± 2.2% ID/g, p < 0.05) (Figure S4), indicating that the
accumulation of the dual-labeled antibody in the tumor was
FRα-mediated.
■ DISCUSSION
This study shows the feasibility of FRα-targeted dual-modality
image-guided surgery of ovarian cancer lesions using 111In-
farletuzumab-IRDye800CW. Intraperitoneal IGROV-1 tumor
lesions were clearly visualized with both microSPECT/CT and
ﬂuorescence imaging, and dual-modality imaging was used to
guide complete tumor resection. These results support the
clinical translation of dual-modality imaging using dual-labeled
farletuzumab, where it could be a valuable tool to assist the
surgeon in cytoreductive surgery in patients with FRα-
expressing tumors.
In the current study dual-modality imaging was optimized in
mice with subcutaneous IGROV-1 xenografts. Biodistribution
studies showed that optimal tumor-to-blood-ratios (3.4−3.7)
Figure 1. Biodistribution proﬁles of indium-111-farletuzumab-
IRDye800CW 3 days p.i. in BALB/c nu/nu mice with sc IGROV-1
tumors at four diﬀerent protein doses.
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were achieved at protein doses up to 30 μg. The decreased
tumor accumulation at higher protein doses probably relates to
antigen saturation at higher protein doses as has been described
previously.24 The biodistribution and tumor accumulation (up
to 43.6% ID/g in the sc model) of 111In-farletuzumab-
IRDye800CW were comparable to those of 111In-DOTA-
farletuzumab as previously reported by Smith-Jones et al.
(tumor uptake 32% ID/g 4 days after injection).14 This ﬁnding
is in accordance with our previous studies that indicated that
conjugation of an antibody with IRDye800CW up to a
substitution ratio of 2 only marginally aﬀects the in vivo
behavior of the antibody.17 Next, the feasibility of dual-modality
imaging was shown in an ip tumor model. Preoperative
microSPECT/CT identiﬁed FRα-expressing intra-abdominal
tumor lesions as small as 1 mm (Figures 2a and 2b).
Intraoperative ﬂuorescence imaging successfully guided resec-
tion of superﬁcially located tumor lesions (Figure 3).
Microscopic analyses conﬁrmed that the resected lesions were
tumor lesions (Figure S3), and a colocalization was seen
between the radioactive and ﬂuorescent signal and FRα-
expression (Figures 4 and S3). Coinjection of an excess of
unlabeled farletuzumab resulted in signiﬁcant reduction of
accumulation of dual-labeled farletuzumab in tumor tissue
(Figure S4). This indicates that the uptake of dual-labeled
farletuzumab in tumor lesions is mainly due to speciﬁc binding
of farletuzumab to FRα. However, nonspeciﬁc tracer uptake
may also contribute to tumor accumulation because of the
enhanced permeability and retention eﬀect (EPR) in tumor
lesions.
Since ovarian cancer mainly spreads within the abdominal
cavity and lesions develop on the surface of abdominal organs, a
clear contrast between tumors and the abdominal organs is a
requirement for sensitive intraoperative detection of ovarian
cancer lesions. In the current study, high accumulation of dual-
labeled farletuzumab in tumor tissue was seen, while
accumulation in the normal abdominal tissues was low as
predicted by lack of farletuzumab’s cross-reactivity to murine
FRα. This led to a high tumor-to-normal contrast as shown in
Figures 2 and 4. Thus, ﬂuorescence imaging could be a useful
aid to improve surgery of advanced stage ovarian cancer
patients. In addition, ﬂuorescence imaging could also be used to
improve staging of ovarian cancer patients. Accurate staging of
lower stage ovarian cancer patients is important to decide if
adjuvant therapy is indicated. After comprehensive surgical
staging approximately 30% of ovarian cancer patients are
upstaged, since (micro)metastases are found in the uterus and/
or fallopian tubes, in the lymph nodes, and in peritoneal,
Figure 2. MicroSPECT/CT shows multiple intraperitoneal IGROV-1 tumors as small as 1 mm (a, coronal view; b, sagittal view). Due to the high
tumor-to-normal tissue ratio and tumor-to-liver ratio, only uptake in tumor tissue is visualized. After resection of the abdominal skin, multiple tumor
deposits were observed macroscopically (white circles in c) and were visualized with ﬂuorescence imaging (d). Furthermore, ﬂuorescence imaging
identiﬁed additional tumor lesions that were barely visible with the naked eye (square in c).
Figure 3. Detection of superﬁcially located tumor lesions by
ﬂuorescence imaging (a) and ﬂuorescence image-guided surgery of
intraperitoneal IGROV-1 tumors (b).
Figure 4. Autoradiography (a) and ﬂuorescence imaging (b) of a
tissue section of the mouse oviduct revealed an area with high
accumulation of dual-labeled farletuzumab. H&E staining (c) of this
same tissue section showed that this area corresponded with a 0.25
mm tumor lesion located near the oviduct. The FRα-staining on an
adjacent tissue section conﬁrmed that this lesion expressed FRα (d).
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omental, or adhesion biopsies.25 Targeted intraoperative
ﬂuorescence imaging could guide the surgeon to tumor tissue
and thereby improve staging and cytoreductive surgery.
A nontargeted ﬂuorescence imaging approach based on the
enhanced permeability and retention eﬀect using indocyanine
green has been investigated by Tummers et al.26 In this study,
ovarian cancer lesions appeared ﬂuorescent, but a false-positive
rate of 62% was found.26 Currently, several trials are ongoing
that demonstrate the value of targeted intraoperative
ﬂuorescence imaging.5,27−29 The FRα is an ideal marker for
targeted imaging in ovarian cancer patients, whereas the folate
receptor beta has limited value, because it is expressed on
activated macrophages and to a lesser extent on ovarian cancer
lesions.9,10,30 Recently it was shown that 16 to 29% additional
lesions could be detected using FRα-targeted ﬂuorescence
imaging using folate-analogues (EC17 and OTL38).31,32 A clear
advantage of folate-analogues over using intact antibodies is the
shorter time that is needed to obtain an optimal tumor-to-
normal tissue contrast (several hours versus several days).
However, false positive rates of 23% were found in both
studies.31,32 With EC17, this can partly be attributed to
autoﬂuorescence of benign tissue in the 500 nm range. Near-
infrared ﬂuorescence imaging with OTL38 has the advantage of
lower autoﬂuorescence and a higher tissue penetration depth,
leading to a better tumor-to-normal tissue contrast, as shown
previously.33 Also, folate analogues are not FRα speciﬁc, but
may also bind the folate receptor beta on activated macro-
phages.31,32 111In-farletuzumab-IRDye800CW has the advan-
tages that farletuzumab only recognizes FRα and that imaging
can be performed in the near-infrared range.34
However, even in the near-infrared range, the penetration
depth of light restricts ﬂuorescence imaging to superﬁcially
located tumor lesions. The advantage of using a radiolabel is
that it can be visualized preoperatively with SPECT/CT
imaging and that it can be used intraoperatively to localize
deeply seeded tumors with a gamma probe or hand-held
SPECT camera. Using dual-labeled imaging, deeper tumors can
ﬁrst be localized with a gamma probe, and after surgical
exposure ﬂuorescence imaging can be used to guide tumor
resection and assess the surgical cavity for residual disease. Due
to the small size of a mouse, gamma probe detection was not
feasible in this preclinical study. Dual-modality imaging may be
achieved using a dual-labeled probe or coinjection of two
separate agents. The disadvantage of coinjection of two
separate agents is the potentially diﬀerent biodistribution and
clearance of the agents. In a dual-labeled approach the
radiosignal and the ﬂuorescent signal originate from the same
molecule. This has the advantage that both signals can serve as
an internal control for each other, e.g., a positive radiosignal in
tissue precludes that the ﬂuorescent signal is due to
autoﬂuorescence. Another advantage of using a radiolabel in
the preclinical setting is that it allows for easy quantiﬁcation of
the accumulation of 111In-farletuzumab-IRDye800CW in
tissues, whereas the quantiﬁcation of a ﬂuorescent signal can
be challenging.35 When combining ﬂuorescent dyes with
radioisotopes, radiolysis of the ﬂuorescent molecule may
occur, a phenomenon that can be prevented by adding reactive
oxygen scavengers like ascorbic acid.36 Considering that
radiolysis is limited with indium-111-labeled compounds that
are injected shortly after radiolabeling,36 no speciﬁc precautions
were taken in the current study.
When translating the current results to the clinical situation,
one has to consider that the sensitivity of the imaging systems
used in the clinical situation diﬀers from that of the ones used
in preclinical studies. Furthermore, in the clinical setting tumors
may be more heterogeneous in terms of FRα expression and
tumor physiology compared to the tumors in this mouse
model. These factors may lead to more variation in the tumor
uptake of the tracer. The feasibility of FRα-targeted dual-
modality imaging was shown in an ip IGROV-1 tumor model,
but feasibility should be shown in additional FRα-expressing
tumor models. Also, the tumor-targeting characteristics of our
tracer could be further assessed by using bioluminescence
imaging in a luciferase expressing IGROV-1 tumor model.
Other limitations in the current study included the lack of
farletuzumab’s cross-reactivity to murine FRα which may be
present in normal tissue, as well as that dual-modality imaging
was performed in a nonascitic tumor model. Patients with
advanced stage ovarian cancer often develop ascites in which
circulating tumor cells will be present. This may lead to an
increased background signal in preoperative SPECT images due
to accumulation of dual-labeled farletuzumab in the ascites.
However, this did not appear to be a problem in the previous
studies where FRα-targeted imaging has been performed.5,14
Since ascites is removed at the start of surgery, this
phenomenon will not hamper intraoperative ﬂuorescence
imaging.
■ CONCLUSION
In conclusion, this study shows the feasibility of FRα-targeted
SPECT/ﬂuorescence imaging using 111In-farletuzumab-IR-
Dye800CW in ovarian cancer in vivo. The next step will be
to evaluate the value of dual-modality imaging and
ﬂuorescence-guided surgery of advanced stage ovarian cancer
patients.
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